1. Introduction {#s0005}
===============

Alzheimer\'s Disease (AD) is the most common cause of dementia ([@bb0005], [@bb0060], [@bb0225], [@bb0280]). Due to the predicted demographic changes in the population with an increasing proportion of elderly individuals, the number of patients affected by dementia and its precursor, mild cognitive impairment (MCI) due to AD, is expected to rise up dramatically over the next decades ([@bb0005]). Research for a more accurate and earlier diagnosis of AD, particularly in its preclinical stages ([@bb0280]), is ongoing and will be the basis for the implementation of new and earlier treatment strategies.

The diagnosis of MCI or dementia due to AD is still based on clinical criteria. The main criterion is the presentation of cognitive decline typically including memory, language and visuospatial functions that is not explained by a major psychiatric disorder. For the diagnosis of dementia, this decline has to be severe enough to interfere with the individual\'s ability to perform activities of daily living ([@bb0190]). To differentiate MCI or dementia due to AD from other forms of cognitive impairment, several biomarkers are available ([@bb0190]). These biomarkers fall into two main categories: First, biomarkers denoting evidence of amyloid-beta (Aβ) protein deposition in the brain (low cerebrospinal fluid (CSF) Aβ~42~ and positive amyloid- positron emission tomography (PET) imaging), and most likely yielding evidence of the AD specific pathophysiological process. The second category encompasses biomarkers that indicate the progressive neuronal degeneration that takes place in the brain, and is less AD-specific, including elevated CSF tau protein, decreased ^18^fluorodeoxyglucose (FDG) uptake in FDG-PET and atrophy on structural MRI of the brain ([@bb0190]). These biomarkers either expose the patient to radiation (PET imaging) or involve an invasive procedure (lumbar puncture for CSF analysis), and are thus not suited for repeated measurements.

Structural MRI is a non-invasive method, but whole brain atrophy as detected on routine scans develops rather late in the course of the disease and is therefore not useful to diagnose pre-dementia stages ([@bb0150]). A more specific approach is the measurement of hippocampal atrophy, which can already be present in pre-dementia stages ([@bb0125]). Since manual volumetry is time consuming and rater dependent, automated segmentation tools have been developed ([@bb0100], [@bb0125], [@bb0195], [@bb0300]). These tools have shown promising results within research settings but their broad implementation into clinical routine is still lacking ([@bb0070], [@bb0105], [@bb0180]). Another important MRI method is diffusion tensor imaging (DTI), which assesses the restricted diffusion of water in tissue. DTI has predominantly been used for white matter tract integrity but recent studies have also demonstrated its potential for assessing the integrity of small gray-matter structures such as the hippocampus ([@bb0015], [@bb0090]). In AD, DTI reveals microstructural alterations within the hippocampus by pathologically elevated mean diffusivity (MD) ([@bb0055], [@bb0090], [@bb0315]), but its role for the diagnosis of AD is not yet clear ([@bb0090]). In sum, despite advances in biomarker research over the past years, we still lack non-invasive diagnostic tools to sensitively detect the disease in early stages ([@bb0010], [@bb0280]), and to predict individual disease progression ([@bb0125]).

Magnetic resonance elastography (MRE) of the brain is a promising new candidate among the non-invasive diagnostic methods ([@bb0220]). MRE assesses tissue structure through its mechanical properties. In principle, shear waves are being introduced into the brain by an external mechanical vibration source ([@bb0110], [@bb0170], [@bb0240]). The image acquisition of the induced tissue deformation is then synchronized to the external vibration source. In this way, different time steps of the propagating waves are captured. Finally, the wave fields are mathematically inverted to calculate viscoelastic parameters ([@bb0075]). These derived viscoelastic parameters reflect the microstructural integrity of the neuronal-glial matrix ([@bb0255]). There are two main viscoelastic parameters that are both derived from the complex shear modulus *G\**: the magnitude of the shear modulus (\|*G\**\|) stands for the softness or elasticity of the tissue while the phase angle (*φ*) provides an indication of the viscous, i.e., damping properties of the tissue ([@bb0240]).

Previous studies have demonstrated the decrease of brain viscoelastic parameters due to physiological aging ([@bb0245]) and due to neurodegenerative ([@bb0175]) and neuroinflammatory disorders ([@bb0080], [@bb0265], [@bb0310]). In dementia due to AD, MRE detected decreased overall brain stiffness ([@bb0205], [@bb0215]). Similar results were found for behavioral variant fronto-temporal dementia, a much rarer form of dementia ([@bb0145]). However, pathology in AD is known to advance from specific regions, most notably the medial temporal lobe including the hippocampus ([@bb0030], [@bb0150]). Whereas the deposition of amyloid-plaques starts in the temporal neocortex and entorhinal cortex, the hippocampus is known to show early tau aggregation ([@bb0040]). The importance of the hippocampus for memory encoding and retrieval and the association of structural integrity of the hippocampus and memory performance have been widely demonstrated ([@bb0285]).

Fortunately, recent advances in MRE research including the introduction of multifrequency MRE (MMRE) now allow us to compute a higher resolution of the anatomical structures in the elasticity maps (two independent parameter maps of the magnitude (\|*G\**\|) and the phase angle (*φ*)) and therefore enabled the analysis of the viscoelastic properties of smaller brain regions ([@bb0045], [@bb0115], [@bb0155]).

In this proof-of concept study, we therefore investigated whether MMRE can detect differences in the elasticity of the hippocampus between patients with clinical diagnosis of dementia due to AD (as defined by the NINCDS-ADRDA criteria for probable dementia due to AD ([@bb0185], [@bb0190])) and healthy controls (HC). First, we aimed to ascertain that MMRE is capable of detecting differences in the elasticity of small brain regions such as the hippocampus. Second, we hypothesized that patients with clinical diagnosis of dementia due to AD show decreased hippocampal stiffness compared to HC. Finally, we asked if the combination of elasticity with two well-known MRI-derived parameters, i.e., hippocampal atrophy (measured as hippocampal volume) and microstructure (indicated by mean diffusivity of the hippocampus) would further improve diagnostic accuracy.

2. Methods {#s0010}
==========

2.1. Patients and controls {#s0015}
--------------------------

Patients were recruited from the memory clinic of the Department of Neurology (Charité University Hospital, Berlin). All patients had been given a clinical diagnosis of dementia before entering the study and met the NINCDS-ADRDA criteria for probable dementia due to AD ([@bb0185], [@bb0190]). The diagnostic procedure in our memory clinic comprises history-taking with the patient and a knowledgeable informant (mostly the spouse or other family member) and an objective cognitive assessment firstly through short "bedside" testing like the Mini-Mental State Examination (MMSE). Additionally, blood results (including electrolytes, blood count, kidney and liver parameters, TSH, vitamin B12 and folic acid levels) and brain imaging (either CT or MRI, but preferably MRI) are reviewed and the patient is then sent for neuropsychological testing by an experienced neuropsychologist. In our memory clinic a clinical diagnosis of probable dementia due to AD is given if the criteria outlined in the NIA guidelines from 2011 ([@bb0190]) are fulfilled.

All patients who receive a diagnosis of probable dementia due to AD are counseled to have a lumbar puncture performed, in order to exclude an inflammatory cause of the dementia and in order to detect amyloid- and tau-protein levels in the CSF. Amyloid-PET is not available within the clinical routine in our center. By definition, the detection of amyloid biomarkers is not necessary for establishing a clinical diagnosis of probable dementia due to AD and is not recommended for routine diagnostic purposes in the NIA guidelines from 2011 ([@bb0190]).

All patients included in this study had undergone the above-described diagnostic process and for patients who had undergone a lumbar puncture, the results from the CSF analysis were considered. One patient had additionally undergone an amyloid-PET. For this patient the results from the PET-scan were considered. Lumbar punctures, CSF analyses or amyloid-PET were not performed for study-purposes only.

Healthy controls were recruited from the community via advertisement. They had no subjective cognitive impairments, scored at least 26 on the MMSE, and underwent a standardized medical interview and neurological examination. Exclusion criteria for both groups comprised severe medical, neurological or psychiatric disease (other than dementia in the patient group), major brain pathologies identified on MRI scans like territorial stroke or brain tumor and contraindications for undergoing MRI (such as claustrophobia or presence of an implanted pacemaker).

Given reports of age- and gender-related differences in elasticity measures of the brain ([@bb0245], [@bb0250]), groups were matched for age and gender.

The participants signed written informed consent prior to study related procedures and received a small compensation for study participation. The study was approved by the Ethics Committee of the Charité University Hospital Berlin, Germany, and was conducted in accordance with the declaration of Helsinki.

2.2. Neuropsychological testing {#s0020}
-------------------------------

Neuropsychological assessment for all participants included the MMSE as a screening measure (see above), followed by the German version of the Consortium to Establish a Registry for Alzheimer\'s Disease (CERAD) neuropsychological assessment battery in the extended version, the CERAD-Plus (see <https://www.memoryclinic.ch/de/main-navigation/neuropsychologen/cerad-plus>). The CERAD-Plus consists of the following subtests (in order of administration): 1) Verbal Fluency, 2) modified Boston-Naming-Test (BNT; maximum 15 points), 3) the MMSE (maximum score of 30), 4) Word-List-Learning (sum of three learning trials; maximum score of 30), 5) Figure-Construction (maximum score of 11), 6) Word-List-Recall (maximum score of 10), 7) Word-List-Recognition (maximum score of 10), and 8) Figure-Recall (maximum score of 11), 9) Trail-Making-Test A, 10) Trail-Making-Test B and 11) Phonemic Fluency. All subtests of the CERAD-Plus were administered according to standard procedures, except for the MMSE, which was taken from the screening procedures. Additionally we calculated a composite total CERAD score, as proposed by Chandler et al., by adding up the results of 6 subtests (Verbal Fluency, modified BNT, Word-List-Learning, Word-List-Recall, Word-List-Recognition and Figure-Construction) with a maximum score of 100, followed by a factor to correct for age, gender and education ([@bb0050]).

2.3. MRI and MMRE protocol {#s0025}
--------------------------

Participants first underwent a structural MRI scan, followed by the MMRE sequence (3 T Siemens Trio MR-System) using a 12-channel head coil at the Berlin Center for Advanced Neuroimaging. The 3D structural scanning protocol consisted of T1-weighted magnetization prepared rapid gradient echo (MPRAGE) imaging (TR = 1900 ms, TE = 2.52 ms, 192 sagittal slices, voxel size = 1.0 × 1.0 × 1.0 mm^3^, flip angle = 9°) and a diffusion-weighted spin-echo echo-planar imaging (EPI) sequence (TR = 7500 ms, TE = 86 ms, 61 axial slices, voxel size = 2.3 × 2.3 × 2.3 mm^3^; 64 directions with a *b*-value of 1000 s/mm^2^ and 10 with a *b*-value of 0 s/mm^2^). An additional T2-weighted fluid attenuated inversion recovery (FLAIR) sequence was acquired in order to exclude structural abnormalities. The Structural Imaging protocol (MPRAGE, FLAIR and diffusion weighted imaging) lasted 20 min.

The MMRE were performed using a single-shot spin-echo EPI-based MRE sequence ([@bb0075]). The MMRE setting is described in detail in ([@bb0295]) and shown in [Fig. 1](#f0005){ref-type="fig"}. Full 3D wave fields were acquired at 7 mechanical frequencies (30 to 60 Hz, 5 Hz increments) in 16 contiguous coronal slices and by an image resolution of 1.9 × 1.9 × 1.9 mm^3^ (FoV: 190 × 160 mm, TR = 2980 ms, TE = 71 ms, 8 instances of the wave cycle). In total, we had an acquisition time of 7 min for a full MMRE protocol.Fig. 1MRE setup: A custom-designed nonmagnetic driver based on piezoelectric ceramics is mounted at the end of the patient table. The vibrations are transduced by a carbon fiber rod, which is connected to a custom-designed head cradle located inside the head coil. The vibrations induce a gentle nodding motion of the head.Fig. 1

The total imaging time was 27 min. In between the structural scan and the MMRE, the participants had a short break in order to set up the MRE-head-cradle, where the participant would sit up and lay back down. They did not leave the scanner during this break. Overall, the scanning procedure was well tolerated by all 42 final participants of the study. Three Patients did not tolerate being in the scanner at all and were therefore excluded from the study.

2.4. Image processing {#s0030}
---------------------

Analyses of the individual T1- and diffusion-weighted images (DTI) were performed with FSL (fsl version 4.1; <http://www.fmrib.ox.ac.uk/fsl>). The hippocampus volumes were segmented from the individual T1-structural images (FSL-FIRST, fsl version 4.1). Individual hippocampal volumes were adjusted to the total intracranial volume (TIV) according to previous studies ([@bb0235]) using the following formula: adjusted volume = raw volume -- *b* × (TIV- mean TIV). The formula is based on the analysis of covariance approach and the coefficient *b* represents the slope of regression of a region of interest volume on TIV. Preprocessing of DTI data included eddy current and motion correction and extraction of non-brain tissue and was in line with previous studies ([@bb0160], [@bb0305]): Eddy current and head-motion correction were performed in FSL by means of an affine registration to the reference (b0) volume ([@bb0275]). The corrected data were skull-stripped by applying the FSL Brain Extraction Tool ([@bb0270]). Next, the tensor model was fitted to the diffusion data using the FMRIB Diffusion Toolbox ([@bb0020], [@bb0275]) to obtain individual 3D maps of mean diffusivity (MD). Images were inspected visually to identify and correct inaccurate brain extraction, registration or segmentation.

From the MMRE-images, we obtained two independent parameter maps of the elasticity measures by using an algorithm (multifrequency dual elasto-visco (MDEV) inversion) that was used in earlier studies ([@bb0045], [@bb0075], [@bb0115], [@bb0135], [@bb0290]). This algorithm implies frequency independence of the mechanical properties within the used frequency range in MMRE and provides two independent parameter maps of the magnitude (\|*G\**\|) and the phase angle (*φ*) of the complex shear modulus *G\**. As described above, \|*G\**\| provides an indication of the tissue elasticity and *φ* provides an indication of the damping properties or viscosity of the tissue ([@bb0240]). Both parameters are model-free and provide another representation of the storage and loss modulus in MRE. Additionally, a T2-weighted MRE magnitude image was generated, which was used for co-registration of the MRE-images with the high-resolution T1-image (MPRAGE).

We chose the hippocampus as region of interest (ROI) and the thalamus as reference region. The choice of reference structure was based on three criteria: First, the thalamus shows widespread neuropathological changes only in advanced stages of the disease ([@bb0030]). Second, the thalamus as a deep gray matter structure can be segmented from the individual high-resolution T1-images (MPRAGE) using FSL-FIRST, and does not require manual delineation of a ROI. Third, our imaging technique with 16 contiguous coronal slices only permitted a limited choice of clearly defined brain structures that were fully included in the imaging zone.

Both regions were segmented from the individual T1-structural images (FSL-FIRST, fsl version 4.1) and then co-registered to the native space elasticity parameter maps (FSL-FLIRT). The segmented regions were used as masks for the elasticity and viscosity parameter maps \|*G\**\| and *φ*. Additionally, we generated a whole brain white matter (WM) mask (see [Fig. 2](#f0010){ref-type="fig"}). Within all masks median values were extracted.Fig. 2The three regions of interest (ROIs) (green: whole brain white matter, blue: thalamus, red: hippocampus) are visualized at T2-weighted MRE magnitude images on the left. In the middle, two example parameter maps of \|*G\**\| in Pascal (Pa) and two example parameter maps of *φ* are visualized. On the right, two example maps of MD (mean diffusivity) are visualized, each for a patient (clinical diagnosis of dementia due to AD) (upper row) and a healthy control (HC) subject (lower row). AD: patients with clinical diagnosis of dementia due to Alzheimer\'s disease. \|*G\**\|: magnitude of the shear modulus *G\**. HC: healthy controls. MD: mean diffusivity. Pa: Pascal. *φ*: phase angle (dimensionless). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 2

2.5. Statistical analysis {#s0035}
-------------------------

Group characteristics were compared using independent *t*-tests for parametric variables, chi-square tests for binary variables and non-parametric tests if data were not sufficiently normally distributed (no unimodal distribution or \| skewness \| \> 1).

The discriminative properties of the four measures: \|*G\**\|, *φ*, MD and volume in the hippocampus, were calculated using receiver operating characteristics (ROC) analyses. We estimated the area under the ROC curve (AUC) with 95% confidence intervals. From the ROC curve of \|*G\**\| an optimal cutoff was visually defined to calculate sensitivity and specificity as well as the positive and negative predictive values. In a secondary analysis, we compared the ROC curves of the single variables and generated ROC curves of combinations of different measures (STATA version 13.1). Paired sample statistical techniques were used for the comparison of two biomarkers. The method exploits the mathematical equivalence of the AUC to the Mann-Whitney U-statistic ([@bb0065]). For testing models with more than one marker against models using only one marker, we used a likelihood-ratio-test.

To analyse the relationship between elasticity and diffusivity we performed bivariate correlation analyses and reported the Pearson coefficient r. For all analyses, a two-tailed significance level of α = 0.05 was considered. For this proof-of-concept study in which the association of viscoelastic measures of the hippocampus with a clinical diagnosis of Alzheimer\'s disease was analyzed for the first time, no adjustment for multiple testing was applied.

Statistical analyses were performed using IBM SPSS Statistics 22 and STATA version 13.1.

3. Results {#s0040}
==========

3.1. Demographic characteristics {#s0045}
--------------------------------

21 patients with clinical diagnosis of dementia due to AD and 21 HC participated in the study. Demographical data and clinical scores of both groups are shown in [Table 1](#t0005){ref-type="table"}. Groups were comparable with regard to age, gender and years of education. As expected the two groups differed in their MMSE score.Table 1Demographical data, clinical scores.Table 1AD (*N* = 21)HC (N = 21)Age (yrs)74 \[67--80\]75 \[66--79\]Female10 (48%)10 (48%)Yrs of education14 ± 315 ± 3MMSE (points)20 \[16--22\]29 \[28--30\]Yrs since diagnosis2 ± 1--[^1]

In the patient group, clinical diagnosis of dementia due to AD had been established for an average of about two years. In 18 of 21 patients, information about CSF-analysis was available. One patient underwent an additional amyloid-PET and was found to be positive for amyloid-pathology on the PET-scan after previously having had negative results in CSF. An overview of the biomarker distribution is shown in [Table 2](#t0010){ref-type="table"}.Table 2Biomarkers for patient group.Table 2AD (*N* = 21)CSF available18 (86%) CSF normal (tau & Aβ)6 (28%) Low Aβ (ratio[a](#tf0005){ref-type="table-fn"})10 (48%) Only raised tau2 (10%)Additional amyloid-PET done1[b](#tf0010){ref-type="table-fn"} (5%) Amyloid-PET positive1 (5%)Presence of Aβ-pathology (CSF + PET)11 (52%)[^2][^3][^4]

As expected the groups differed in their results on the composite total CERAD score and in their results of the individual subtests of the CERAD-Plus neuropsychological assessment battery. An overview of the results is shown in Supplementary Table I.

3.2. Mechanical properties (elasticity and viscosity) {#s0050}
-----------------------------------------------------

In the patient group, \|*G\**\|- and *φ*-values in the hippocampus ROI were significantly lower than in the HC group. For the thalamus, we observed comparable \|*G\**\|- values between the two groups, but significantly lower *φ*-values in the patient group. Within the whole brain WM mask we observed both significantly lower \|*G\**\|- and *φ*-values in the patient group (see [Table 3](#t0015){ref-type="table"}). [Fig. 3](#f0015){ref-type="fig"} visualizes the group results of \|*G\**\| in the three regions using boxplots.Fig. 3Boxplots of \|*G\**\| and *φ* of the three regions with overlaid dotplot of the raw data: hippocampus, thalamus and whole brain white matter according to the high-resolution MDEV inversion. N = 21 in each group. AD: patients with clinical diagnosis of dementia due to Alzheimer\'s disease. HC: healthy controls. Pa: Pascal. \|G\*\|: magnitude of the shear modulus *G\**. *φ*: phase angle (dimensionless).Fig. 3Table 3Main outcome parameters of elasticity and viscosity.Table 3AD (*N* = 21)HC (N = 21)p\|*G*\*\| of hippocampus (in Pa)863 ± 1471076 ± 190\< 0.001[a](#tf0015){ref-type="table-fn"}*φ* of hippocampus0.43 ± 0.060.51 ± 0.07\< 0.001[a](#tf0015){ref-type="table-fn"}\|*G*\*\| of thalamus (in Pa)1208 ± 2511283 ± 2030.293[a](#tf0015){ref-type="table-fn"}*φ* of thalamus0.65 ± 0.110.71 ± 0.080.043[a](#tf0015){ref-type="table-fn"}\|*G*\*\| of WM (whole brain) (in Pa)1387 ± 1591544 ± 1290.001[a](#tf0015){ref-type="table-fn"}*φ* of WM (whole brain)0.59 ± 0.050.63 ± 0.050.007[a](#tf0015){ref-type="table-fn"}[^5][^6]

To test the stability of the extracted values of \|*G\**\| and *φ*, we performed control analyses with slightly larger and slightly smaller ROIs for the three regions (hippocampus, thalamus, whole brain white matter ROI). For this, we enlarged and eroded the ROIs by one and by two voxels in the three dimensions. This did not change the results shown in [Fig. 3](#f0015){ref-type="fig"} with regard to differences between the groups (data not shown).

3.3. Hippocampal diffusivity and volume {#s0055}
---------------------------------------

MD was significantly higher in the patient group indicating a loss of integrity of tissue microstructure. Comparison of hippocampal volumes between groups revealed significantly smaller hippocampal volumes in the patient group (see [Table 4](#t0020){ref-type="table"}).Table 4Diffusivity and volume of hippocampus.Table 4AD (N = 21)HC (N = 21)pMD (× 10^− 3^ mm^2^/s)1.31 ± 0.231.13 ± 0.090.003[a](#tf0020){ref-type="table-fn"}Volume (× 10^3^ mm^3^)2.83 ± 0.513.53 ± 0.40\< 0.001[a](#tf0020){ref-type="table-fn"}[^7][^8]

3.4. Comparison of elasticity, diffusivity and volume {#s0060}
-----------------------------------------------------

To test the discriminative value of \|*G\**\| in the hippocampus for the distinction between the HC versus the patient group, we plotted the ROC curve ([Fig. 4](#f0020){ref-type="fig"}a), which yielded an AUC of 0.81 \[95%CI 0.68--0.94\]. From the ROC curve and the output table we determined a cutoff with a sensitivity not lower than 80% and corresponding highest possible specificity. That yielded a cut-point of \|*G\**\| = 980 Pa and corresponds to a sensitivity of 86% and a specificity of 67%. The positive predictive value was 72% and the negative predictive value was 82%.Fig. 4Individual ROC curves for a) \|*G\**\|, b) MD, c) volume of the hippocampus and d) combined ROC-curve of \|*G\**\|, MD and volume. ROC: receiver operating characteristic. AUC: Area under (ROC) curve. CI: 95% confidence interval. \|*G\**\|: magnitude of the complex shear modulus *G\**. MD: mean diffusivity.Fig. 4

We also plotted the ROC curve for *φ*, which yielded an AUC of 0.79 \[95%CI 0.66--0.93\]. Then we generated a combined ROC curve of \|*G\**\| and *φ* with an AUC of 0.83 \[95%CI 0.70--0.95\] and compared this to \|*G\**\| and *φ* alone using a likelihood ratio test (graphs not shown). The combined AUC did not perform better than either parameter alone (compared to \|*G\**\| alone *p* = 0.243; compared to *φ* alone *p* = 0.104). Given that the combination of \|*G\**\| and *φ* did not improve the discriminative value compared to using \|*G\**\| alone, only the \|*G\**\|-properties of the hippocampus were considered in subsequent analyses.

The AUC values of \|*G\**\|, volume and MD in the hippocampus were all \> 0.8 (see [Fig. 4](#f0020){ref-type="fig"}). Combining these three variables (\|*G\**\|, MD and volume) into one ROC curve further improved the AUC value to 0.90 \[95%CI 0.81--0.99\]. This value was significantly higher than \|*G\**\| only (*p* = 0.005), MD only (*p* = 0.020), or volume only (*p* = 0.043) using a likelihood ratio test.

Additionally, we performed correlation analyses for the relationship between elasticity and viscosity of the hippocampus with MD of the hippocampus. The scatterplots are shown in the Supplementary Fig. II. We found an inverse correlation for both viscoelastic measures with a lower elasticity or viscosity of the hippocampus correlating with a higher mean diffusivity.

3.5. Subgroup analysis by amyloid-pathology {#s0065}
-------------------------------------------

Within our group of patients with dementia, 11 had proven Aβ-pathology (CSF or PET), whereas 7 had normal amyloid-levels in CSF and 3 patients did not receive any diagnostics in search of Aβ-pathology. We therefore performed subgroup analyses comparing the Aβ-positive subgroup with the rest of the AD patients. We found no significant differences between the subgroups with regard to age, gender, MMSE, years since diagnosis, or \|*G\**\|, MD and volume of the hippocampus. This result did not change after excluding the 3 patients without any diagnostic procedure (data not shown). We additionally conducted an analysis comparing only the group of Aβ-positive patients with healthy controls. This did not change the results for the differences in elasticity measures within the hippocampus between the two groups (data not shown). Correlation analyses between CSF amyloid-β and elasticity of the hippocampus and between CSF amyloid-β and elasticity of the whole brain white matter mask did not show any significant correlations (all Pearson r\'s \< 0.3).

4. Discussion {#s0070}
=============

With this proof-of-concept study, we were able to show that MMRE is capable of detecting differences in the elasticity of small brain regions such as the hippocampus between patients with dementia, regardless of amyloid status, and HC. Moreover, we demonstrated that stiffness within the hippocampus, determined using MMRE, is lower in patients with clinical diagnosis of dementia of the AD type than in HC. Plotting the ROC curve for \|*G\**\|of the hippocampus yielded a sensitivity of 86% and a specificity of 67% (cutoff at \|*G*\*\| = 980 Pa). These values were lower than those of amyloid-specific but invasive methods such as CSF analyses or amyloid-PET (best CSF parameter (CSF Aβ42/total tau) with 97% sensitivity and 83% specificity; amyloid-PET composite score with 85% sensitivity and 87% specificity ([@bb0230])). Finally, we demonstrated that the diagnostic sensitivity of our non-invasive approach was further improved by combining hippocampal stiffness with two other MRI-based hippocampal parameters, i.e., hippocampal volume and mean diffusivity; yielding a significantly higher AUC than either of the three parameters alone.

Similar to other studies ([@bb0205], [@bb0215]), patients showed reduced stiffness within a whole brain white matter mask, indicating widespread neurodegenerative brain tissue changes due to the disease. However, our finding that stiffness within the thalamus, a gray matter brain region known to be affected late in the course of AD ([@bb0030]), did not show clear differences between the groups, emphasizes the specificity of the MRE findings for degeneration patterns typical for AD ([@bb0030], [@bb0150]).

Studies with MRE in mice, using a murine model of Parkinson\'s Disease, have demonstrated an association between the number of neurons in a brain region and its stiffness, indicating that a loss of neurons would lead to decreased stiffness ([@bb0120], [@bb0165]). One study with a murine model of Alzheimer\'s disease found an overall decreased brain stiffness compared to wildtype mice ([@bb0210]). [@bb0200] showed an age-dependent cell loss in the hippocampus of AD mice that correlated with reduced stiffness. However there was no analysis that correlated stiffness changes with amyloid deposition. As the deposition of amyloid-plaques precedes neuronal loss and atrophy ([@bb0035], [@bb0060]), future studies in murine Alzheimer-models should investigate whether amyloid deposition alone already causes a measurable change in regional brain stiffness. To date, it remains unclear if stiffness changes are mainly due to deposition of amyloid-plaques in the AD brain, or if reduced stiffness is indicative for tau-pathology, neuronal loss, or inflammatory processes in the course of the disease ([@bb0095], [@bb0130], [@bb0140]). Our finding that stiffness did not differ between Aβ-positive patients with dementia and Aβ-negative patients with dementia would suggest that Aβ-pathology is less important for stiffness changes than other factors such as tau-pathology, neuronal loss, and/or inflammation. This hypothesis should be tested in animal models.

Finally, we were interested in comparing, and subsequently combining, the new parameter of hippocampal stiffness with two more widely employed MRI-derived parameters, i.e., hippocampal volume and microstructure (as determined by mean diffusivity).

As shown in [Fig. 4](#f0020){ref-type="fig"}, the ROC curve analyses demonstrated a comparable performance as predictive diagnostic test between the new parameter of hippocampal stiffness and the established MRI-derived parameters of hippocampal volume and diffusivity. The combined ROC curve of hippocampal stiffness, volume and mean diffusivity significantly improved prediction compared to the predictive values achieved by either of the three parameters alone. Since all three parameters require one single MRI only, their combination may constitute a promising approach, not only for diagnosis but also for predicting conversion to dementia in early stages of AD, a hypothesis to be evaluated in future studies.

Further, the absolute difference in stiffness and volume was approximately 20% between patients and HC compared to only approximately 10% difference in diffusivity (see [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}). However, volumetry is highly dependent on the precision of hippocampal segmentation ([@bb0100], [@bb0070], [@bb0125]) and this might influence its reliability as imaging marker in follow-up examinations. The diagnostic accuracy of hippocampal MMRE was not influenced by the size of the ROI in the present study. We therefore expect MMRE to play an increasing role in MRI-based AD assessment in the future, in particular when ongoing technical improvements of wave stimulation and inversion methods are translated into a higher consistency of values.

The main limitation of this study is the small number of subjects investigated in each group. Therefore, the present results should be replicated in studies with larger samples. Also it would be desirable to confirm or refute amyloid-pathology (either in CSF or by amyloid-PET) in all individuals within the patient group. We addressed this uncertainty by performing subgroup analyses, comparing the Aβ-positive subgroup with the Aβ-negative subgroup, which allowed for conclusions towards underlying pathology, and additionally performing analyses with and without the patients for whom no information on amyloid- pathology was available. This did not change the main results of the study. Further, since the resolution of the MRE images was 1.9 mm cubic voxels, partial-volume effects might occur that affect the precision of the ROIs especially in a small region like the hippocampus ([@bb0260]). Therefore, we performed additional analyses with eroded ROIs, which did not change the results. Future studies might technically address this issue by improving resolution of the MRE images. Unlike MD measurement, MRE parameter maps were not corrected for eddy currents and motions. EPI-based MRE is susceptible to field distortions near air-tissue interfaces which should be corrected as recently proposed by [@bb0085]. This method will be implemented in future MMRE studies to increase the spatial reliability of voxel-wise stiffness analysis.

Due to the choice of our imaging technique using coronal slices for the MRE, we were limited in analyzing further brain structures and chose the thalamus as reference structure even though studies by Braak and Braak found that parts of the thalamus are involved in neuropathological changes during AD starting in stage 2 ([@bb0025]). This means that the thalamus is not a reference structure in the sense that it is not involved in AD pathology at all; rather, it shows involvement in the pathophysiological process in more advanced stages, and we therefore expected to find less difference in viscoelastic measures between healthy subjects and patients for the thalamus than for the hippocampus.

5. Conclusions and outlook {#s0075}
==========================

Since the hippocampus is targeted in the neurodegenerative process of AD early on ([@bb0030], [@bb0150]), detection of decreased hippocampal stiffness may be a promising noninvasive biomarker for early diagnosis and progression monitoring in the future. Given previous histological findings in animal models, and the present results demonstrating that hippocampal stiffness did not differ between Aβ-positive and Aβ-negative patients with dementia, stiffness may be a sensitive marker for tau-pathology, neuronal loss, and/or inflammation, but not amyloid-pathology. This hypothesis is supported by the fact that tau-pathology, rather than amyloid-pathology, starts in the hippocampus ([@bb0040]). Future studies should evaluate an area known to harbor early amyloid-pathology, like the posterior cingulum/precuneus or the entorhinal cortex, to determine whether differences in amyloid-positive versus amyloid-negative patients can be detected by MMRE.

The results of this study motivate further investigation whether MMRE can detect decreased brain stiffness in early stages of the disease, and whether these changes predict clinical decline. To answer these questions, longitudinal studies in pre-dementia stages of AD would be most suitable.
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[^1]: Data are median \[IQR\], mean ± SD or number (%); AD: patients with clinical diagnosis of dementia due to Alzheimer\'s Disease; HC: healthy controls; yrs.: years; MMSE: Mini Mental State Examination.

[^2]: Data are number (%); Aβ: beta-amyloid protein; a ratio below 0.40 is considered pathological. AD: patients with clinical diagnosis of dementia due to Alzheimer\'s Disease; CSF: Cerebrospinal fluid; PET: Positron Emission Tomography.

[^3]: Aβ ratio: ratio of Aβ1-42 × 10/Aβ1-40.

[^4]: One patient underwent amyloid-PET after being Aβ-negative in CSF (independent of the conduction of this study).

[^5]: AD: patients with clinical diagnosis of dementia due to Alzheimer\'s disease, HC: healthy controls, \|*G*\*\|: magnitude of the complex shear modulus G\*, *φ*: phase angle, Pa: Pascal, WM: white matter; values are given as mean ± SD.

[^6]: Independent *t*-test.

[^7]: AD: Patients with clinical diagnosis of dementia due to Alzheimer\'s disease, HC: healthy controls, MD: mean diffusivity, values are given as mean ± SD.

[^8]: Independent t-test.
